IP Library Granted Patent US 11,607,439
Granted Patent B2
US 11,607,439 · App. 16/983,715 · Granted Mar 21, 2023

Natural drugs for the treatment of inflammation and melanoma

Inventor: Bruce L. Howe (San Diego, CA)
Assignee: HERBALIFE INTERNATIONAL, INC.
A61K36/9068A61K9/127A61K9/14A61K31/12A61K31/56A61K31/685A61K36/324A61K36/9066
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,607,439
App. No.
16/983,715
Granted
Mar 21, 2023
Kind
B2
Abstract

The invention is directed to natural drug compositions comprising turmeric, boswellia and ginger. Methods for the use of the inventive drug compositions in the treatment of inflammatory disorders and melanoma are within the scope of the invention.

Claims (13)

1. A composition consisting essentially of:

50% turmeric extract,

30% boswellia extract, and

20% ginger extract,

wherein the composition is encapsulated within a liposome.

2. The composition of claim 1 , wherein the turmeric extract is standardized to about 95% curcuminoids.

3. The composition of claim 2 , wherein the turmeric extract is about 1% lecithin and about 1% turmeric oil.

4. The composition of claim 1 , wherein the boswellia extract is standardized to about 30% boswellic acid.

5. The composition of claim 4 , wherein the boswellic acid consists essentially of acetyl-11-keto-beta-boswellic acid.

6. The composition of claim 4 , wherein the boswellia extract is about 1% lecithin and about 1% boswellia oil.

7. The composition of claim 1 , wherein the ginger extract is standardized to about 20% gingerols.

8. The composition of claim 7 , wherein the ginger extract is about 1% lecithin and about 1% ginger oil.

9. The composition of claim 1 , wherein the composition inhibits nitric oxide production in a human by about 10% at a concentration of 0.1 mg/ml administered to the human.

Assignments (7)
PATENT SECURITY AGREEMENT - NOTES Recorded Apr 29, 2026
From: HERBALIFE INTERNATIONAL, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075494/0983 →
RELEASE OF PATENT SECURITY AGREEMENT RECORDED AT REEL 067091/FRAME 0032 AND REEL 067091/FRAME 0325 Recorded Apr 29, 2026
From: CITIBANK, N.A.
To: HERBALIFE INTERNATIONAL, INC.; HERBALIFE INTERNATIONAL OF AMERICA, INC.
Reel/Frame 075499/0715 →
ASSIGNMENT OF PATENT SECURITY AGREEMENT Recorded Apr 30, 2024
From: JEFFERIES FINANCE LLC, AS RESIGNING AGENT
To: CITIZENS BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 067265/0162 →
SECURITY INTEREST Recorded Apr 12, 2024
From: HERBALIFE INTERNATIONAL, INC.
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 067091/0032 →
SECURITY INTEREST Recorded May 25, 2022
From: HERBALIFE INTERNATIONAL, INC.
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 060008/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2021
From: NUTRAGEN HEALTH INNOVATIONS, INC.
To: HERBALIFE INTERNATIONAL, INC.
Reel/Frame 057456/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2020
From: HOWE, BRUCE L.
To: NUTRAGEN HEALTH INNOVATIONS, INC.
Reel/Frame 054158/0561 →
Continuity (3)
Continuation 15829716 · Dec 1, 2017
Provisional Application 62435608 · Dec 16, 2016
Related Publication 20200360459A1 · Nov 19, 2020